Guardant Health (GH) Competitors

Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk.

Which has more volatility and risk, GH or CDNA?

Guardant Health has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, CareDx has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.

Do analysts rate GH or CDNA?

Guardant Health presently has a consensus target price of $40.60, suggesting a potential upside of 32.33%. CareDx has a consensus target price of $29.60, suggesting a potential upside of 32.32%. Given Guardant Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe Guardant Health is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	0 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.94
CareDx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Do insiders & institutionals believe in GH or CDNA?

92.6% of Guardant Health shares are owned by institutional investors. 5.5% of Guardant Health shares are owned by company insiders. Comparatively, 4.9% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has stronger earnings and valuation, GH or CDNA?

CareDx has lower revenue, but higher earnings than Guardant Health. CareDx is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$563.95M	6.72	-$479.45M	-$4.24	-7.24
CareDx	$280.32M	4.28	-$190.28M	-$2.70	-8.29

Does the MarketBeat Community favor GH or CDNA?

CareDx received 159 more outperform votes than Guardant Health when rated by MarketBeat users. However, 70.07% of users gave Guardant Health an outperform vote while only 66.17% of users gave CareDx an outperform vote.

Company	Underperform	Outperform
Guardant Health	Outperform Votes 281 70.07%	Underperform Votes 120 29.93%
CareDx	Outperform Votes 440 66.17%	Underperform Votes 225 33.83%

Is GH or CDNA more profitable?

CareDx has a net margin of -45.90% compared to Guardant Health's net margin of -74.02%. CareDx's return on equity of -53.70% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-74.02%	-1,200.44%	-29.88%
CareDx	-45.90%	-53.70%	-30.42%

Does the media favor GH or CDNA?

In the previous week, Guardant Health had 2 more articles in the media than CareDx. MarketBeat recorded 5 mentions for Guardant Health and 3 mentions for CareDx. CareDx's average media sentiment score of 0.53 beat Guardant Health's score of 0.30 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Guardant Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CareDx	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Guardant Health beats CareDx on 11 of the 18 factors compared between the two stocks.